Peginterferon Alfa



Combined with:

Indications and Reactions:

Role Indications Reactions
Secondary
Hepatitis C 71.5%
Chronic Hepatitis C 11.2%
Product Used For Unknown Indication 8.1%
Angioimmunoblastic T-cell Lymphoma 1.2%
Immunosuppression 1.2%
Prophylaxis 1.1%
Hepatic Cirrhosis 0.8%
Cryoglobulinaemia 0.6%
Diabetes Mellitus 0.5%
Hiv Infection 0.5%
Hypertension 0.5%
Constipation 0.5%
Drug Use For Unknown Indication 0.4%
Pruritus 0.4%
Adjustment Disorder With Mixed Anxiety And Depressed Mood 0.3%
Depression 0.2%
Hepatitis 0.2%
Insomnia 0.2%
Portal Hypertension 0.2%
Abdominal Pain Upper 0.2%
Rash 24.9%
Vomiting 12.4%
Off Label Use 10.0%
Weight Decreased 7.5%
Thrombocytopenia 5.0%
White Blood Cell Count Decreased 4.5%
Drug Ineffective 3.5%
Urinary Tract Infection 3.5%
Nausea 3.0%
Renal Failure Acute 3.0%
Tremor 3.0%
Fatigue 2.5%
Pain 2.5%
Pyrexia 2.5%
Rash Generalised 2.5%
Neutropenia 2.0%
Pruritus 2.0%
Rectal Haemorrhage 2.0%
Retinopathy 2.0%
Stevens-johnson Syndrome 2.0%
Concomitant
Hepatitis C 75.3%
Product Used For Unknown Indication 13.7%
Chronic Hepatitis C 3.9%
Anaemia 1.2%
Hiv Infection 1.0%
Pancytopenia 0.8%
Pruritus 0.8%
Blood Pressure 0.6%
Hypertension 0.6%
Diabetes Mellitus 0.4%
Depression 0.2%
Diuretic Therapy 0.2%
Gastritis 0.2%
Hypothyroidism 0.2%
Pain 0.2%
Panic Disorder 0.2%
Schizophrenia 0.2%
Vitamin Supplementation 0.2%
Rash 26.9%
Vomiting 19.4%
Fatigue 6.5%
Thrombocytopenia 5.4%
Death 3.2%
Diarrhoea 3.2%
Inappropriate Schedule Of Drug Administration 3.2%
Off Label Use 3.2%
Pruritus 3.2%
Rash Generalised 3.2%
Toxic Epidermal Necrolysis 3.2%
Circulatory Collapse 2.2%
Drug Ineffective 2.2%
Eczema 2.2%
Intestinal Obstruction 2.2%
Malaise 2.2%
Nausea 2.2%
Rash Erythematous 2.2%
Rectal Abscess 2.2%
Swelling Face 2.2%